Skip to main content
. 2021 Jun 17;11:652193. doi: 10.3389/fonc.2021.652193

Figure 3.

Figure 3

The MPC-associated genetic alterations that can be confirmed by the validation cohort. (A) Genetic alteration profile of the validation cohort with either MPC-predominant (MPP) tumors (left panel) or other histological subtypes (right panel). (B–D) The cross-validated MPC-associated genetic changes by coupling the P values from the validation cohort with the discovery/reference cohorts that underwent different analysis: comparing MPC-dissected samples from high MPC tumors of the discovery cohort with reference cohort (B), comparing all MPC-dissected samples of the discovery cohort with reference cohort (C), and Jonckheere’s trend analysis of mutation frequency ranking from dissected samples from high MPC tumors, dissected samples from low MPC tumors, the matched non-MPC dissected samples to reference LADC samples (D). *p < 0.05, **p < 0.01.